In conclusion, the PADDOCK and PALOMINO trials demonstrate that daily subcutaneous pegcetacoplan injection is an effective treatment for PNH-related anemia in patients not previously treated with C5 inhibitor therapy. The gene discussed is C5; the disease is anemia.